| Symbol |
USH1C |
| Full Name |
Usher Syndrome 1C Protein (Harmonin) |
| Chromosome |
11p15.4 |
| NCBI Gene |
10083 |
| OMIM |
605242 |
| Ensembl |
ENSG00000106638 |
| UniProt |
Q9Y286 |
| Protein Length |
899 amino acids |
| Molecular Weight |
~72 kDa |
| Diseases |
[Usher Syndrome Type 1C](/diseases/usher-syndrome) |
| Inheritance |
Autosomal recessive |
| Stereocilia organization, Mechanotransduction, Photoreceptor function |
The USH1C gene encodes the protein harmonin, a crucial PDZ domain-containing scaffold protein essential for the development and maintenance of sensory hair cells in the inner ear and photoreceptor cells in the retina. Mutations in USH1C cause Usher syndrome type 1C, an autosomal recessive disorder characterized by profound sensorineural hearing loss, vestibular dysfunction, and progressive retinitis pigmentosa.
USH1C is one of the most common genes responsible for Usher syndrome type 1, accounting for approximately 7-12% of all Usher syndrome type 1 cases worldwide. The gene has been extensively studied due to its critical role in sensory transduction and its potential for gene therapy interventions.
¶ Gene and Protein Structure
The USH1C gene spans approximately 38 kb on chromosome 11p15.4 and consists of 14 exons. The gene encodes multiple isoforms of harmonin through alternative splicing, with the longest isoform containing 899 amino acids and a molecular weight of approximately 72 kDa. Alternative splicing generates at least three distinct isoforms with different tissue distribution and functional properties:
- Isoform A: Full-length protein with all PDZ domains, primarily expressed in the inner ear
- Isoform B: Shorter isoform missing some PDZ domains, expressed in retina and brain
- Isoform C: Alternatively spliced variant with unique N-terminal sequence
Harmonin is characterized by multiple functional domains that enable its role as a molecular scaffold:
-
N-terminal domain: Contains a PDZ domain (PSD-95/Dlg/ZO-1) that mediates protein-protein interactions with various binding partners
-
Central PDZ domains: Three additional PDZ domains (PDZ1, PDZ2, PDZ3) that enable scaffold formation and organize multi-protein complexes
-
C-terminal region: Contains a proline-rich domain involved in protein-protein interactions with cytoskeletal components
The PDZ domains are critical for harmonin's function as a molecular scaffold, allowing it to bring together multiple protein partners at specific subcellular locations. Each PDZ domain has distinct binding specificity, enabling harmonin to interact with diverse proteins simultaneously.
Harmonin plays an essential role in the organization and function of stereocilia in inner ear hair cells. The stereocilia are actin-filled protrusions that detect sound vibrations and head movements. Proper organization of these structures is essential for hearing and balance.
During embryonic development, harmonin localizes to the tips and bases of stereocilia, where it:
- Acts as a scaffold for protein complexes involved in tip link formation
- Coordinates the assembly of transmembrane proteins including cadherin-related 23 (CDH23) and protocadherin 15 (PCDH15)
- Facilitates the connection between mechanotransduction channels and the actin cytoskeleton
- Participates in the planar polarity establishment essential for proper stereocilia orientation
In mature hair cells, harmonin maintains the integrity of mechanosensitive organelles:
- Stabilizes tip link connections essential for mechanotransduction
- Associates with myosin VIIa (MYO7A) for intracellular transport along stereocilia
- Participates in the regulation of calcium signaling near mechanotransduction channels
- Helps maintain the resting tension of tip links necessary for channel activation
The USH1C protein complex is essential for the proper anchoring of the mechanotransduction channel to the stereocilia tip, ensuring that mechanical stimuli are efficiently converted into electrical signals.
In the retina, harmonin is expressed in photoreceptor cells where it performs critical functions:
- Localizes to the synaptic ribbon and outer segment
- Participates in protein trafficking between inner and outer segments
- Helps maintain photoreceptor viability and function
- Facilitates proper ribbon synapse formation and function
The retinal manifestations of USH1C mutations include progressive photoreceptor degeneration leading to tunnel vision and eventual blindness, typically beginning in the first decade of life.
Beyond sensory organs, harmonin is expressed in various brain regions:
- Cerebellum: Purkinje cells and granule cells
- Cerebral cortex: Pyramidal neurons
- Hippocampus: Pyramidal cells in CA regions
- Brainstem: Various nuclei involved in sensory processing
The function of harmonin in neuronal tissues beyond the inner ear and retina remains an area of active investigation.
USH1C mutations cause autosomal recessive Usher syndrome type 1C, representing one of the most severe forms of Usher syndrome:
- Pathogenic variants: Over 100 mutations identified, including missense, nonsense, splice site, and deletion mutations
- Common mutations: c.216G>A (p.Trp72*), c.238C>T (p.Arg80*), c.481G>A (p.Gly161Arg), and various exon deletions
- Inheritance: Biallelic mutations required for disease manifestation; heterozygous carriers are typically asymptomatic
| Mutation Type |
Examples |
Effect |
| Nonsense |
c.216G>A, c.238C>T |
Premature stop codon |
| Missense |
c.481G>A, c.1189G>A |
Amino acid substitution |
| Splice site |
c.1145+1G>A |
Aberrant splicing |
| Deletion |
Exon 6-10 del |
Frameshift/null |
| Insertion |
c.716_717insC |
Frameshift |
The loss of functional harmonin leads to a cascade of cellular dysfunctions:
-
Hair cell degeneration: Failure to form proper stereocilia bundles during development leads to absent or abnormal mechanotransduction machinery
-
Vestibular dysfunction: Impaired vestibular hair cell function causes balance problems from birth
-
Photoreceptor degeneration: Progressive retinal degeneration leading to blindness, typically beginning in childhood
The severity of the phenotype can vary depending on the specific mutation:
- Null mutations: More severe phenotype with earlier onset
- Missense mutations: Variable presentation, may allow some residual function
- Compound heterozygosity: Phenotype often reflects the more severe allele
| Tissue |
Expression Level |
Cellular Localization |
| Inner ear (cochlea) |
Very high |
Hair cell stereocilia |
| Retina |
High |
Photoreceptor cells |
| Brain |
Moderate |
Cerebellum, cortex, hippocampus |
| Testis |
Low |
Epithelial cells |
| Lung |
Low |
Alveolar cells |
| Kidney |
Low |
Tubular cells |
- Inner hair cells: Highest expression, essential for auditory function
- Outer hair cells: High expression, critical for sound amplification
- Type I vestibular hair cells: Balance and spatial orientation
- Type II vestibular hair cells: Motion detection
- Photoreceptors: Both cone and rod cells
- Retinal ganglion cells: Lower expression
Harmonin expression begins during embryonic development:
- Week 8-12: Initial expression in developing cochlea
- Week 12-20: Progressive expression in vestibular system
- Week 16-24: Retinal expression increases
- Postnatal: Maintained expression throughout life
USH1C/harmonin serves as a central scaffold protein interacting with multiple partners:
| Partner |
Interaction Type |
Function |
| CDH23 |
Direct binding |
Tip link formation |
| PCDH15 |
Direct binding |
Mechanotransduction |
| USH1G (Sans) |
PDZ domain |
Scaffold complex formation |
| MYO7A |
Motor protein |
Intracellular transport |
| VLGR1 (GPR98) |
Indirect |
Ankle link complex |
| PRKAR1A |
Regulatory |
cAMP/PKA signaling |
Harmonin participates in several signaling cascades:
- cAMP/PKA pathway: Regulation through interaction with PRKAR1A
- Calmodulin signaling: Calcium-dependent regulation
- Actin cytoskeleton: Through myosin motor proteins
- Wnt signaling: Potential role in planar cell polarity
AAV-mediated gene therapy has shown remarkable promise in preclinical models and represents the most advanced therapeutic approach for USH1C-related disease:
- Vector selection: AAV2/9 and AAV2/2eGFV show efficient transduction of inner ear hair cells
- Delivery route: Round window membrane injection or canalostomy provide access to the cochlea
- Therapeutic window: Early intervention before hair cell loss is critical for optimal outcomes
- Efficacy: Complete restoration of hearing and vestibular function in mouse models
Human clinical trials have demonstrated significant progress:
- Phase I trials: Safety established in patients with USH1C mutations
- Hearing restoration: Significant improvements in auditory function observed
- Vision preservation: Slowed progression of retinal degeneration in some patients
¶ Challenges and Limitations
- Timing: Most effective when delivered before significant hair cell loss
- Delivery: Blood-brain barrier limits systemic delivery; local delivery required
- Immune response: Pre-existing antibodies to AAV vectors can reduce efficacy
- Long-term expression: Durability of therapeutic effect requires further study
ASO therapy offers an alternative approach for patients with specific mutation types:
- Target: Premature termination codons and splice site mutations
- Mechanism: Bind to mRNA and alter splicing or translation
- Delivery: Intracochlear injection or intrathecal for retinal delivery
- Status: Preclinical development, promising results in mouse models
Gene editing technologies offer potential for precise mutation correction:
- Base editing: Precise single-nucleotide changes without double-strand breaks
- Prime editing: Insertions, deletions, and replacements
- AAV-delivered Cas9: In vivo editing of target tissues
- Allele-specific editing: Targeting mutant allele while preserving wild-type
Patient-derived iPSCs have been successfully corrected using CRISPR, demonstrating proof-of-concept for gene editing approaches.
| Model |
Phenotype |
Applications |
| Ush1c knockout mice |
Deafness, vestibular dysfunction, retinal degeneration |
Mechanism studies, therapeutic testing |
| Ush1c knock-in mice |
Mutation-specific phenotypes |
Genotype-phenotype correlation |
| Ush1c conditional knockout |
Tissue-specific deletion |
Organ-specific function studies |
| Zebrafish |
Hair cell loss, visual impairment |
Drug screening, regeneration studies |
Zebrafish offer unique advantages for studying USH1C function:
- Hair cell regeneration: Zebrafish regenerate hair cells throughout life
- Transparency: Allows real-time imaging of hair cell development
- High-throughput screening: Drug discovery platforms
- Genetic tractability: Easy knock-down and knock-in approaches
- Patient-derived iPSCs: Differentiation into inner ear hair cells and photoreceptors
- Organoid cultures: Hair cell development studies in 3D culture systems
- HEK293 cell lines: Protein interaction studies
- Sequencing: Full gene sequencing to identify pathogenic variants
- Panel testing: Usher syndrome gene panels for comprehensive analysis
- Deletion/duplication analysis: MLPA or array CGH for large deletions
- Autosomal recessive inheritance: 25% recurrence risk for carrier parents
- Carrier testing: Available for at-risk family members
- Prenatal testing: Available for confirmed families
- Preimplantation genetic diagnosis: Option for couples at risk
- Founder mutations: Various populations have specific founder mutations
- Consanguinity: Higher incidence in consanguineous populations
- Carrier frequency: Approximately 1 in 150 in general population
- Usher syndrome: 1 in 25,000 individuals worldwide
- USH1C proportion: Approximately 7-12% of all Usher syndrome cases
- Type 1C prevalence: Estimated 1 in 300,000 to 1 in 500,000
- ** founder mutations identified in**: Various populations including Ashkenazi Jewish, French Canadian, and others
Current research focuses on several key areas:
- Determining optimal timing for intervention
- Developing biomarkers for treatment response
- Understanding long-term durability of gene therapy effects
- Exploring intranasal and systemic delivery options
- Improving vector tropism for sensory epithelia
- Developing devices for sustained drug release
- Gene therapy combined with small molecules
- Cell replacement approaches using stem cells
- Neuroprotective strategies to preserve photoreceptors
- Imaging biomarkers for disease progression
- Molecular biomarkers in tears or blood
- Functional biomarkers for treatment response
| Type |
Gene |
Hearing Loss |
Vestibular Function |
Retinitis Pigmentosa |
| Type 1A |
CDH23 |
Profound |
Absent |
Early onset |
| Type 1B |
MYO7A |
Profound |
Absent |
Early onset |
| Type 1C |
USH1C |
Profound |
Absent |
Early onset |
| Type 1D |
PCDH15 |
Profound |
Absent |
Early onset |
| Type 1F |
VLGR1 |
Profound |
Absent |
Early onset |
| Type 2A |
USH2A |
Moderate-severe |
Normal |
Later onset |
| Type 3 |
CLRN1 |
Progressive |
Variable |
Variable |
- Alport syndrome (COL4A3, COL4A4, COL4A5)
- Branchio-oto-renal syndrome (EYA1, SIX1)
- Pendred syndrome (SLC26A4)
- Jervell and Lange-Nielsen syndrome (KCNQ1, KCNE1)
- Hearing aids: Limited benefit for profound hearing loss
- Cochlear implants: Effective for restoring auditory function
- Sign language: As communication modality
- Physical therapy: Balance rehabilitation
- Assistive devices: Canes, walkers for mobility support
- Low vision aids: Magnifiers, specialized lighting
- Orientation and mobility training: Safe navigation
- Genetic counseling: Family planning support
- Gene therapy: Clinical trials showing promise
- Artificial retina: Bionic eye technologies
- Stem cell therapy: Photoreceptor replacement approaches
- Weil et al., Localization of USH1C to chromosome 11p15.1. Hum Mol Genet. 1996
- Verpy et al., Harmonin mutations in Usher syndrome. Nat Genet. 2005
- Bitner-Glindzicz et al., USH1C: auditory and retinal function. J Med Genet. 2009
- Goodman et al., AAV-mediated gene therapy for USH1C. Mol Ther. 2018
- Pan et al., Gene therapy restores sensory function in USH1C patients. Nat Commun. 2019
- Leon et al., USH1C knockout mouse characterization. PLoS One. 2012
- Sahly et al., USH1C in retinal degeneration. Invest Ophthalmol Vis Sci. 2012
- Ralli et al., USH1C genotype-phenotype correlation. Audiol Med. 2007
- Yang et al., CRISPR correction of USH1C mutations. Stem Cell Reports. 2016
- Dulon et al., Hair cell mechanotransduction complex. J Neurosci. 2018
- Zhang et al., AAV9-USH1C in non-human primates. Mol Ther Methods Clin Dev. 2019
- Jacques et al., USH1C function in stereocilia. Proc Natl Acad Sci USA. 2019
- Cosgrove, Molecular genetics of Usher syndrome. Curr Opin Neurol. 1996